Comparative effects of dexamethasone and bergenin on chronic bronchitis and their anti-inflammatory mechanisms based on NMR metabolomics

Ren, Xiaolei; Ma, Shuangshuang; Wang, Juan; Tian, Simin; Fu, Xiaorui; Liu, Xinfeng; Li, Zhongfeng; Zhao, Baosheng; Wang, Xueyong

doi:10.1039/c6mb00041j

Cited by 28 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 24 However, more studies found that the concentration of BCAAs is reduced in COPD patients 19 and models. 25 The elevated level of valine in our experiment is consistent with the previous phenotyping study. 26 The reason for the different results is that previous metabolomics experiments did not use CT classification as a criterion for screening patients with COPD.…”

Section: Discussionsupporting

confidence: 92%

<sup>1</sup>H-NMR-based metabolic profiling of healthy individuals and high-resolution CT-classified phenotypes of COPD with treatment of tiotropium bromide

Tan¹,

Yang²,

Fu³

et al. 2018

COPD

View full text Add to dashboard Cite

BackgroundHeterogeneity of COPD results in different therapeutic effects for different patients receiving the same treatment. COPD patients need to be individually treated according to their own characteristics. The purpose of this study was to explore the differences in different CT phenotypic COPD by molecular metabolites through the use of metabolomics.MethodsAccording to the characteristics of CT imaging, 42 COPD patients were grouped into phenotype E (n=20) or phenotype M (n=24). Each COPD patient received tiotropium bromide powder for inhalation for a therapeutic period of 3 months. All subjects were assigned into phenotype E in pre-therapy (EB, n=20), phenotype E in post-therapy (EA, n=20), phenotype M in pre-therapy (MB, n=22), phenotype M in post-therapy (MA, n=22), or normal control (N, n=24). The method of metabolomics based on 1H nuclear magnetic resonance (1H-NMR) was used to compare the changes in serum metabolites between COPD patients and normal controls and between different phenotypes of COPD patients in pre- and post-therapy.ResultsPatients with COPD phenotype E responded better to tiotropium bromide than patients with COPD phenotype M in terms of pulmonary function and COPD assessment test scores. There were differences in metabolites in COPD patients vs normal control people. Differences were also observed between different COPD phenotypic patients receiving the treatment in comparison with those who did not receive treatment. The changes of metabolites involved lactate, phenylalanine, fructose, glycine, asparagine, citric acid, pyruvic acid, proline, acetone, ornithine, lipid, pyridoxine, maltose, betaine, lipoprotein, and so on. These identified metabolites covered the metabolic pathways of amino acids, carbohydrates, lipids, genetic materials, and vitamin.ConclusionThe efficacy of tiotropium bromide on COPD phenotype E is better than that of phenotype M. Metabolites detected by 1H-NMR metabolomics have potentialities of differentiation of COPD and healthy people, discrimination of different COPD phenotypes, and giving insight into the individualized treatment of COPD.

show abstract

Section: Discussionsupporting

confidence: 92%

<sup>1</sup>H-NMR-based metabolic profiling of healthy individuals and high-resolution CT-classified phenotypes of COPD with treatment of tiotropium bromide

Tan¹,

Yang²,

Fu³

et al. 2018

COPD

View full text Add to dashboard Cite

show abstract

“…Currently, high-throughput metabolomics studies have covered phenotypic differentiation, diagnosis, differential diagnosis, and therapeutic intervention, including pulmonary rehabilitation therapy for COPD [4,8,9,10,11]. Various samples including blood/serum/plasma, urine, exhaled breath condensate (EBC), lung tissue, sputum, bronchoalveolar lavage fluid (BALF), etc.…”

Section: Copd-associated Biomarkers In Different Sample Types and mentioning

confidence: 99%

“…Researchers found that carnitine and phenylalanine to tyrosine ratios were associated with increased age in COPD patients [30]. Another study from this team also found BCAAs metabolism and glycolysis dysregulation in serum samples could be adjusted by dexamethasone and bergenin treatment [10].…”

Section: Copd-associated Biomarkers In Different Sample Types and mentioning

confidence: 99%

An Updated Overview of Metabolomic Profile Changes in Chronic Obstructive Pulmonary Disease

Ran

Pang

et al. 2019

Metabolites

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD), a common and heterogeneous respiratory disease, is characterized by persistent and incompletely reversible airflow limitation. Metabolomics is applied to analyze the difference of metabolic profile based on the low-molecular-weight metabolites (<1 kDa). Emerging metabolomic analysis may provide insights into the pathogenesis and diagnosis of COPD. This review aims to summarize the alteration of metabolites in blood/serum/plasma, urine, exhaled breath condensate, lung tissue samples, etc. from COPD individuals, thereby uncovering the potential pathogenesis of COPD according to the perturbed metabolic pathways. Metabolomic researches have indicated that the dysfunctions of amino acid metabolism, lipid metabolism, energy production pathways, and the imbalance of oxidations and antioxidations might lead to local and systematic inflammation by activating the Nuclear factor kappa-light-chain-enhancer of activated B cells signaling pathway and releasing inflammatory cytokines, like interleutin-6 (IL-6), tumor necrosis factor-α, and IL-8. In addition, they might cause protein malnutrition and oxidative stress and contribute to the development and exacerbation of COPD.

show abstract

“…Bergenin ( Figure 1 ) is a naturally occurring C-glucoside of 4-O-methylgallic acid found in many plant species. Several therapeutic applications of bergenin have been proposed in the literature, e.g., anti-ulcerative [ 10 ], hepatoprotective [ 11 , 12 ], anticancer [ 13 ], neuroprotective [ 14 , 15 ], antidiabetic [ 16 ], anti-inflammatory [ 17 , 18 , 19 , 20 , 21 , 22 ], antinociceptive [ 17 , 23 ], and antioxidant [ 12 , 16 , 24 , 25 , 26 , 27 ]. Considering that oxidative stress and neuroinflammation play key roles in the pathophysiology of DN [ 28 ], the above-mentioned properties of bergenin may contribute to the effective control of painful DN.…”

Section: Introductionmentioning

confidence: 99%

Bergenin Reduces Experimental Painful Diabetic Neuropathy by Restoring Redox and Immune Homeostasis in the Nervous System

Villarreal

Santos

Lauria

et al. 2020

IJMS

View full text Add to dashboard Cite

Diabetic neuropathy is a frequent complication of diabetes. Symptoms include neuropathic pain and sensory alterations—no effective treatments are currently available. This work characterized the therapeutic effect of bergenin in a mouse (C57/BL6) model of streptozotocin-induced painful diabetic neuropathy. Nociceptive thresholds were assessed by the von Frey test. Cytokines, antioxidant genes, and oxidative stress markers were measured in nervous tissues by ELISA, RT-qPCR, and biochemical analyses. Single (3.125–25 mg/kg) or multiple (25 mg/kg; twice a day for 14 days) treatments with bergenin reduced the behavioral signs of diabetic neuropathy in mice. Bergenin reduced both nitric oxide (NO) production in vitro and malondialdehyde (MDA)/nitrite amounts in vivo. These antioxidant properties can be attributed to the modulation of gene expression by the downregulation of inducible nitric oxide synthase (iNOS) and upregulation of glutathione peroxidase and Nrf2 in the nervous system. Bergenin also modulated the pro- and anti-inflammatory cytokines production in neuropathic mice. The long-lasting antinociceptive effect induced by bergenin in neuropathic mice, was associated with a shift of the cytokine balance toward anti-inflammatory predominance and upregulation of antioxidant pathways, favoring the reestablishment of redox and immune homeostasis in the nervous system. These results point to the therapeutic potential of bergenin in the treatment of painful diabetic neuropathy.

show abstract

Comparative effects of dexamethasone and bergenin on chronic bronchitis and their anti-inflammatory mechanisms based on NMR metabolomics

Cited by 28 publications

References 32 publications

<sup>1</sup>H-NMR-based metabolic profiling of healthy individuals and high-resolution CT-classified phenotypes of COPD with treatment of tiotropium bromide

<sup>1</sup>H-NMR-based metabolic profiling of healthy individuals and high-resolution CT-classified phenotypes of COPD with treatment of tiotropium bromide

An Updated Overview of Metabolomic Profile Changes in Chronic Obstructive Pulmonary Disease

Bergenin Reduces Experimental Painful Diabetic Neuropathy by Restoring Redox and Immune Homeostasis in the Nervous System

Contact Info

Product

Resources

About